Allosteric Modulators for Selective M4 Receptor Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction, such as schizophrenia, face challenges due to the lack of potent and selective activators for the M4 muscarinic acetylcholine receptor, leading to adverse effects and limited clinical utility.
Innovation Solution
Development of positive allosteric modulators that selectively activate the M4 muscarinic acetylcholine receptor, binding to an allosteric site distinct from the orthosteric site, to enhance receptor activity without inducing desensitization, thereby reducing toxicity and improving tolerability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AChE inhibitors are used to increase acetylcholine levels, then therapeutic efficacy is improved, but gastrointestinal side effects and hepatotoxicity increase
Solution Approach 1:
The patent applies local quality by developing compounds with selective affinity for specific muscarinic receptor subtypes (M1, M3, M5) that are predominantly expressed in the central nervous system, while avoiding activation of peripheral subtypes (M2, M4). This subtype-selective approach allows therapeutic action in the brain without activating peripheral muscarinic receptors that mediate gastrointestinal side effects and other adverse reactions.
2Adaptability or versatility
If selective M4 agonists are developed to treat psychotic disorders, then therapeutic specificity is improved, but selectivity and lack of adverse effects are worsened due to inability to achieve high M4 selectivity
Solution Approach 1:
The patent achieves subtype selectivity through local quality by designing compounds that specifically target M1, M3, and M5 muscarinic receptor subtypes while sparing M2 and M4 subtypes. This is accomplished through structural features that match the binding characteristics of CNS-predominant subtypes, enabling therapeutic efficacy in psychotic disorders without activating peripheral receptors that cause adverse effects.
3Reliability
If mAChR agonists are administered to activate muscarinic receptors, then cholinergic function is improved, but peripheral activation causes adverse effects
Solution Approach 1:
The patent applies segmentation by dividing the muscarinic receptor family into distinct subtype groups with different tissue distributions and functional roles. By targeting specifically M1, M3, and M5 subtypes that are enriched in the CNS, the compounds segment the therapeutic action from peripheral adverse effects, achieving central cholinergic enhancement without peripheral muscarinic activation.
4Reliability
If orthosteric agonists are used to activate muscarinic receptors, then receptor activation is achieved, but desensitization and tolerance develop
Solution Approach 1:
The patent employs allosteric modulators as intermediaries that bind to sites distinct from the orthosteric acetylcholine binding site. These allosteric compounds enhance receptor activation indirectly by modulating the receptor's conformation or affinity for endogenous ligands, rather than directly competing for the orthosteric site. This intermediary mechanism achieves therapeutic receptor activation while avoiding the desensitization and tolerance that characterize direct orthosteric agonists.
Data Source
AI summary
Disclosed herein are thieno[3,2-e][1,2,4]triazolo[1,5-a]pyridin-6-amine, thieno[3,2-e][1,2,4]triazolo[4,3-a]pyridin-3-amine, and imidazo[1,2-a]thieno[3,2-e]pyridin-3-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.